Trial reportJTCVS open2026
Crystalloid cardioplegia versus cold blood cardioplegia in aortic arch surgery: A noninferiority randomized trial.
Trial report in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal cardioplegic solution to use during aortic surgery remains unclear. While cold blood cardioplegia (BCP) has metabolic advantages, crystalloid cardioplegia (CCP) offers practical benefits. This trial investigated whether cold CCP is noninferior to cold BCP in preserving postoperative left ventricular ejection fraction (LVEF). Methods: In this single-center, patient- and assessor-blinded, parallel-group noninferiority randomized trial, 52 adult patients undergoing elective aortic arch replacement were randomized 1:1 to receive cold BCP or CCP. The primary endpoint was LVEF on postoperative day 7. The noninferiority margin was set at -7%. Secondary endpoints included change in LVEF, mortality, low-output syndrome, myocardial infarction (MI), creatine kinase MB isotype (CK-MB) release, left ventricular diastolic dysfunction, right ventricular systolic dysfunction, stroke, atrial fibrillation, pacemaker implantation, mediastinal drainage, reexploration for bleeding, and acute kidney injury. Results: The median aortic cross-clamp time was 96 minutes. Baseline LVEF was similar in the 2 groups (BCP, 61.1 ± 5%; CCP, 61.7 ± 5%; Conclusions: Cold CCP appeared to be noninferior to cold BCP for myocardial protection in elective aortic arch replacement, as suggested by comparable postoperative LVEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.